The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.
In a statement, the company said it is working to achieve full compliance with all applicable requirements for continued listing.
ContraVir is focused on development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection.
